Severity
Moderate
FDA Drug recall · Reported June 24, 2026
CGMP Deviations; deficiencies observed during FDA inspection
Dabur India Limited recalled Med Pride, Bacitracin Zinc Ointment, 1oz (28.3g) per tube, 72 tubes per case, Manufacture… - a moderate-severity action.
Med Pride, Bacitracin Zinc Ointment, 1oz (28.3g) per tube, 72 tubes per case, Manufacture… was recalled by Dabur India Limited in June 24, 2026. Reason: CGMP Deviations; deficiencies observed during FDA inspection. Check the official notice for the remedy. Verify recall #D-0637-2026 with the FDA Drug before acting.
The recall
Dabur India Limited issued this moderate-severity FDA Drug recall-CGMP Deviations; deficiencies observed during FDA inspection.
Sourced from official FDA Drug enforcement records. Verify recall #D-0637-2026 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0637-2026) was formally reported on June 24, 2026, with the manufacturer initiating the action on June 2, 2026. It is classified under Moderate severity (Class II), with a current status of Ongoing. Dabur India Limited is listed as the recalling firm, operating out of Dadra And Nagar Haveli. Federal records list the affected scope as 1185 tubes.
The documented reason for this recall is: CGMP Deviations; deficiencies observed during FDA inspection Distribution data in the federal record shows the product reached: US Nationwide.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,436 drugs & medications recalls on record
Of 88,001 recalls with an agency hazard classification, 19,020 are high severity, 64,468 moderate, and 4,513 low. A further 16,157 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
1185 tubes
Related Recalls
6
6 from same agency
Med Pride, Bacitracin Zinc Ointment, 1oz (28.3g) per tube, 72 tubes per case, Manufactured for: Shield Line LLC, 59 Hook Road, Bayonne, NJ 07002 USA, Made in India, UPC X004WB4LKT.
CGMP Deviations; deficiencies observed during FDA inspection
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Ongoing |
| Recall number | D-0637-2026 |
| Date reported | June 24, 2026 |
| Date initiated | June 2, 2026 |
| Recalling firm | Dabur India Limited |
| Firm location | Dadra And Nagar Haveli |
| Affected scope | 1185 tubes |
| Distribution | US Nationwide. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Two federal-filing-derived peer sets for this notice, both outside the same recalling firm and filing state so the neighborhoods are not firm or geographic containment.
Same archive severity grade (Moderate), closest by report date among other firms and states.
Same product category, closest by report date among other firms and states (deduped against the severity set).
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Showing 5 of 14436 other recalls in this category.
Rohto-Mentholatum (Vietnam) Co., Ltd. · 2026-07-29
Major Pharmaceuticals · 2026-07-29
Rohto-Mentholatum (Vietnam) Co., Ltd. · 2026-07-29
Major Pharmaceuticals · 2026-07-29
Major Pharmaceuticals · 2026-07-29
Compare this recall with Rohto Cooling Eye Drops Max Strength (naphazoline hydrochlo… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported June 24, 2026. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.